AKT1 and differentiated thyroid carcinoma: Furthermore, RAS mutations, identified in many thyroid tumors, particularly in FTC and in the follicular variant of papillary thyroid carcinoma (FV-PTC) [57,61], may enhance thyroid tumorigenesis through their interaction with the PI3K/Akt pathway, which is a common and early event in FTC [62].